• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

KDventures

0.26 SEK

+2.00 %

Less than 1K followers

KDV B

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.00 %
-15.00 %
-0.58 %
-25.07 %
-28.16 %
-71.00 %
-81.53 %
-87.99 %
-99.12 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
193.56M SEK
Turnover
40.24K SEK
Revenue
1.67M
EBIT %
-11,623.95 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
28/8
2026

Interim report Q2'26

13/11
2026

Interim report Q3'26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release2026-06-30 08:00

Ändring av antal aktier och röster i KDventures AB

KDventures
Regulatory press release2026-06-30 08:00

Change of number of shares and votes in KDventures AB

KDventures
Regulatory press release2026-06-26 11:00

Finansinspektionen: Flaggningsmeddelande i KDventures AB

KDventures

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-06-25 10:05

KDventures portföljbolag AnaCardios kliniska studie av läkemedelskandidaten AC01 publicerad i The Lancet

KDventures
Press release2026-06-25 10:05

KDventures’ portfolio company AnaCardio’s clinical study of drug candidate AC01 published in The Lancet

KDventures
Regulatory press release2026-06-23 14:05

KDventures portföljbolag Umecrine Cognition slutför interimanalys i pågående klinisk studie av golexanolon

KDventures
Regulatory press release2026-06-23 14:05

KDventures’ portfolio company Umecrine Cognition completes interim sample size analysis in ongoing clinical study of golexanolone

KDventures
Regulatory press release2026-06-18 08:15

KDventures AB genomför en riktad nyemission om totalt 99 516 667 nya B-aktier och tillförs cirka 23,9 miljoner kronor

KDventures
Regulatory press release2026-06-18 08:15

KDventures AB has carried out a directed issue of a total of 99,516,667 new B shares and raises approximately SEK 23.9 million

KDventures
Regulatory press release2026-06-17 19:40

KDventures AB utreder förutsättningarna för att genomföra en riktad nyemission

KDventures
Regulatory press release2026-06-17 19:40

KDventures AB explores the conditions for carrying out a directed issue

KDventures
Regulatory press release2026-06-08 08:00

KDventures deltar i portföljbolaget Umecrine Cognitions nyemission och skriver ned bokfört värde

KDventures
Regulatory press release2026-06-08 08:00

KDventures participates in portfolio company Umecrine Cognitions’ share issue and writes down book value

KDventures
Press release2026-05-27 08:50

KDventures portföljbolag Umecrine Cognition presenterar data från PBC-patienter som visar att extrem trötthet som det mest besvärande symtomet

KDventures
Press release2026-05-27 08:50

KDventures' portfolio company Umecrine Cognition presents new patient data identifying severe fatigue as the most burdensome symptom in PBC

KDventures
Press release2026-05-13 09:25

KDventures portföljbolag Umecrine Cognition presenterar nya data som belyser behovet av behandling mot trötthet och kognitiva symtom vid PBC

KDventures
Press release2026-05-13 09:25

KDventures’ portfolio company Umecrine Cognition to present new data highlighting the need for central fatigue and cognitive symptom therapies in PBC

KDventures
Regulatory press release2026-05-12 15:56

KDventures årsstämma 2026

KDventures
Regulatory press release2026-05-12 15:56

KDventures’ Annual General Meeting 2026

KDventures
Press release2026-05-11 10:32

Redeye: Redeye Initiates Coverage of KDventures

KDventures